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The periosteum contributes to bone repair and maintenance of cortical bone mass. In contrast to the understanding of bone develop-
ment within the epiphyseal growth plate, factors that regulate periosteal osteogenesis have not been studied as intensively. Osteofibrous
dysplasia (OFD) is a congenital disorder of osteogenesis and is typically sporadic and characterized by radiolucent lesions affecting the
cortical bone immediately under the periosteum of the tibia and fibula. We identified germline mutations in MET, encoding a receptor
tyrosine kinase, that segregate with an autosomal-dominant form of OFD in three families and a mutation in a fourth affected subject
from a simplex family and with bilateral disease. Mutations identified in all families with dominant inheritance and in the one simplex
subject with bilateral disease abolished the splice inclusion of exon 14 in MET transcripts, which resulted in a MET receptor (METD14)
lacking a cytoplasmic juxtamembrane domain. Splice exclusion of this domain occurs during normal embryonic development, and
forced induction of this exon-exclusion event retarded osteoblastic differentiation in vitro and inhibited bone-matrix mineralization.
In an additional subject with unilateral OFD, we identified a somaticMETmutation, also affecting exon 14, that substituted a tyrosine
residue critical for MET receptor turnover and, as in the case of the METD14 mutations, had a stabilizing effect on the mature protein.
Taken together, these data show that aberrant MET regulation via the juxtamembrane domain subverts core MET receptor functions
that regulate osteogenesis within cortical diaphyseal bone.Introduction
The periosteum is a thinmembranous structure that covers
the external surfaces of all bones in mammals. It is
composed of an outer fibrous layer and an inner layer
that contains blood vessels and cells that have the poten-
tial to sponsor the maintenance of the underlying cortical
bone in addition to contributing substantially to fracture
healing.1,2 The regulation of the periosteal cellular
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The Americanthat a subfraction of cells from this population possess
properties of osteochondroprogenitors in that they have
the ability to differentiate into osteoblasts and
chondrocytes.
Osteofibrous dysplasia (OFD [MIM: 607278]) is a devel-
opmental skeletal disorder characterized by radiolucent
lesions located at the periosteal surface of the diaphyseal
cortex, almost exclusively of the tibia and fibula
(Figure 1A), although lesions in the radius and ulna have
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Figure 1. The Clinical, Pathological, and Genetic Basis of Bilateral Osteofibrous Dysplasia
(A) Radiograph of both lower limbs of subject III:6 from family 1 demonstrating gradual resolution of mid-diaphyseal lesions of the tibia
and fibula over 12 years (reproduced with permission from the publisher of Beals and Fraser3). AP, antero-posterior; lat, lateral.
(B) Histology and immunohistochemistry of lesional tissue excised at surgery from subject III:6 (aged 9 years) from family 1 demon-
strating spindle-shaped cells at the center of lesions (arrow) surrounded by osteoid (o); staining for alkaline phosphatase (ALP) is
maximal in the periphery of lesions and absent at the center (arrows); lesions are characterized by rimming osteoblasts staining posi-
tively for the early osteoblastic marker osterix (OSX) and osteoclastic marker tartrate resistant acid phosphatase (TRAP).
(C) Pedigrees of the four families with bilateral OFD and with identified mutations in MET.and typically unilateral, and they spontaneously resolve
during skeletal maturation;4 the residuum is most
commonly mild bowing at the affected site. Prior to their
resolution, secondary complications such as fractures and
non-union and pseudoarthrosis formation can complicate
the condition. Histologically, OFD lesions exhibit ‘‘zonal
architecture’’ characterized by spindle-shaped fibroblast-
like cells in the center of the lesions that are progressively
replaced with peripherally located, more differentiated
cells from the osteoblastic lineage (Figure 1B).5 The cells
lying at the center of the lesions stain for markers of undif-
ferentiated mesenchymal cell states, whereas bridging
zones of osteoid with surface osteoblasts and embedded os-
teocytic cells are interspersed between the lesions.5,6 In
OFD, the unossified zones eventually mineralize after
replacement with normal osteoid and, finally, bone. This
histological progression corresponds with the clinical
and radiographic resolution of the lesions, although
some affected bones exhibit residual bowing (Figure 1A).
Although typically sporadic and unilateral, familial and
bilateral forms of OFD have been described.3,7–9
Here, we have identified germline and somatic muta-
tions in the gene encoding the receptor tyrosine kinase
MET that specifically disrupt the differentially spliced
exon 14 to cause three familial and two simplex cases
of OFD. Alternative splicing of MET (MIM: 164860) regu-
lates the stability of the receptor by determining the inclu-
sion or exclusion of an ubiquitination target within its
cytoplasmic domain.10 Our results indicate that the sta-
bilization of MET while ligand-dependent activation is838 The American Journal of Human Genetics 97, 837–847, Decembmaintained retards osteoblastic differentiation and, as
such, presents MET as a key regulator of cortical bone
osteogenesis.Material and Methods
Ethical Review, Consent, Subject Ascertainment, and
Clinical Descriptions
All subjects were ascertained by physician-initiated referral and
consented to participate under approved protocols MEC/08/08/
094 and 13/STH/56 from the Health and Disability Ethics
Committee, New Zealand and the institutional review boards of
the University of Texas Southwestern Medical Center and the
Hospital for Sick Children, University of Toronto. All index sub-
jects presented with lesions that were located at the periosteal
surface of cortical bone and resolved with time post-fracture
(Figure 1A).3,7,8 All individuals were clinically examined by at least
one of the co-authors, and antero-posterior and lateral radiographs
of both forelegs were obtained for all individuals. Individuals were
assigned as affected if (1) they had clinically or radiologically
evident involvement of the tibia and fibula or (2) historical clinical
or radiographic evidence of involvement. Radiographs of individ-
uals whose clinical or radiographic status was uncertain were
examined by a radiologist who was blinded to the clinical or famil-
ial relationship of those persons within their respective families.
A histological diagnosis of OFD was assigned to lesions that con-
tained rare cells staining for cytoskeletal keratin and exhibited
rimming osteoblasts embedded within osteoid. The distribution
of the disease in affected individuals was almost entirely confined
to the tibia and fibula, although one subject in family 1 had severe
scoliosis, and he and several other family members had variableer 3, 2015
degrees of pectus excavatum. The condition did not appear to
confer enhanced risk of fracture or other orthopedic complica-
tions except for fractures at the site of radiologically evident le-
sions. There was no history of malignant neoplasms, prior to the
age of 50 years, in any family member. More extensive descrip-
tions of families 1, 2, and 4 and their clinical presentations have
been previously published.3,7,9 Control DNA samples and cell
lines were obtained from sex- and age-matched healthy individ-
uals. The University of Otago Animal Ethics Committee approved
the protocols for use of mice in these investigations (ET11/13).
Immunohistochemistry
Human OFD tissue samples were fixed in formalin, decalcified,
and embedded in paraffin. Serial sections were de-paraffinized
and rehydrated through an alcohol gradient to water. Amicrowave
pressure cooker was used for heat-induced epitope retrieval
(15 min, 10 mM citrate buffer [pH 6.0]) for the alkaline phospha-
tase (ab108337) and MET (ab74217) antibodies. No antigen
retrieval was required for the Sp7/osterix antibody (ab22552;
Abcam). Endogenous peroxide activity was blocked with 3%
(v/v) hydrogen peroxide in methanol for 15 min at room temper-
ature, and nonspecific binding was blocked with 2% (v/v) normal
goat sera (Vectorlabs) in PBS with 2% (w/v) BSA for 30 min. Pri-
mary antibody was incubated overnight at 4C and Polinker-1
HRP secondary antibodywas used to detect binding of the primary
antibody (GBI Labs). Normal rabbit serum or monoclonal rabbit
immunoglobulin G was used in control sections.
Linkage
HumanLinkage-12 arrays (Illumina) were used to genotype indi-
viduals from family 1. Genotypes were imported into Aloho-
mora11 forpedigree checkingandremovalofMendelianerrorsprior
to performance of parametric linkage analysis with Allegro v.2.12,13
Custom Capture Chip Construction and Massively
Parallel DNA Sequencing for Family 1
For family 1, customized NimbleGen 1.2M SeqCap capture ar-
rays were designed according to the manufacturer’s instructions
(NimbleGen). Targeted capture and sequencing was performed on
the 454 Sequencing platform (Roche), and subsequent sequence
alignment and calling were performed with proprietary analytic
scripts (Roche).
Exome Sequencing in Family 2
The exomes of four family members from family 2—three affected
(IV-4, IV-10, IV-12) and one unaffected (III-7)—were captured with
the Agilent SureSelect Human All-Exon 50 Mb kit and sequenced
with the Applied Biosystems (ABI) SOLiD 4 system. Sequences
were aligned to the UCSC Genome Browser hg19 reference
sequence with ABI LifeScope software; variants were annotated
with SeattleSeq v.6.21 software. Variants predicting nonsynony-
mous or frameshift changes were further filtered for variants that
were novel (absent in public databases dbSNP, 1000 Genomes,
and the Exome Aggregation Consortium) and shared in exomes
of affected, but not unaffected, family members.
Cell Culture and Exome Sequencing of an Individual
with Sporadic Unilateral OFD
Cells from resected bone tissue were cultured in MEM-a 10% fetal
bovine serum and penicillin/streptomycin (PS; 100 units of potas-
sium penicillin and 100 mg of streptomycin sulfate per 1 ml of cul-The Americanture media) at 37C and 5% CO2 as previously described.
14
DNA was extracted from cultured cells after a single passage.
Whole-exome capture was performed with the TruSeq Exome Kit
(Illumina). Sequencing was performed with the 23 150 bp
paired-end protocol on an Illumina HiSeq 2500 instrument. Reads
were mapped with the Burrows-Wheeler Aligner15, and quality-
control was performed with Picard and the Genome Analysis Tool-
kit (GATK)16. Variants were detected with GATK, and high-quality
novel nonsynonymous variants were identified after exclusion of
those present in dbSNP, the NHLBI Exome Sequencing Project
Exome Variant Server, and an in-house database of control
exomes. For clonal cell isolation, cells were harvested and sorted
into five 96-well plates with an Aria II cell sorter. The 96-well plates
had a ratio of 1:1 fresh and conditioned media. Single cells were
grown for three to four weeks at 37C, and cDNA was prepared
from surviving clonal lines. To detect the variant in lesional tissue,
RNA was extracted with the RNeasy Mini Kit (QIAGEN), and RT-
PCR was performed with the SuperScript III One-Step RT-PCR
System (Invitrogen).Haplotype Analysis
Microsatellites were genotyped on an Applied Biosystems 3730xl
DNA Analyzer, and genotype files were analyzed in GeneMapper
v.4.0 (Applied Biosystems) to assign alleles. Haplotypes were con-
structed manually. The locations of the microsatellites are pre-
sented in Table S5.Cell Transfections and Western Blotting
Human MET WT (wild-type) and METD14 cDNAs were amplified
from HEK293 and H596 cell lines, respectively, and cloned into
commercially available pCMV6-AC-GFP plasmid (Origene) by re-
striction digestion. Previous studies have demonstrated that the
GFP-tagged MET constructs express appropriately at the plasma
membrane and are functionally unimpaired by this modifica-
tion.17 The construct encoding METTyr1003Ser was generated from
the MET WT GFP-tagged clone with a QuikChange Lightning
Site-Directed Mutagenesis Kit (Agilent). Using Lipofectamine
2000 and following the manufacturer’s recommendations, we
transiently transfected HEK293T cells with WT or mutant con-
structs of GFP-tagged full-length human MET with or without
CBL or SIAH1 expression constructs (an unrelated E3 ubiquitin
ligase). After 24 hr, cells were washed with cold 13 PBS and lysed
by the addition of RIPA buffer directly to the cell culture wells.
Whole cell lysates were resolved by reducing SDS-PAGE on a
6% gel and were subjected to immunoblotting with rabbit anti-
MET (1:500) (catalog no. sc-10; Santa Cruz) followed by rabbit
anti-b–actin (1:1,000) (catalog no. 4970; Cell Signaling) antibodies
in 5% non-fat milk.In Situ Hybridization
In situ hybridization was performed on 12 mm cryosections. After
4% paraformaldehyde fixation, sections were acetylated and pre-
hybridized for 2 hr at 60C with hybridization solution (50%
formamide, 53 saline sodium citrate, 500 mg/ml tRNA, 50 mg/ml
heparin, 0.1% Tween 20, 1M citric acid). Hybridization (hybridiza-
tion solutionþ 1 mg/ml probe) was performed overnight at 60C in
a humidified chamber. Slides were washed and processed for stain-
ing as previously described.18 To generate antisense and sense RNA
probes, a mouse Met cDNA fragment was subcloned into pGEMt-
easy with forward primer 50-GCTTGTAAGTGCCCGAAGTG-30
and reverse primer 50-ACATGTCTCTGGCAAGACCG-30. AntisenseJournal of Human Genetics 97, 837–847, December 3, 2015 839
and sense RNA probes were prepared with Not1 and T7 RNA poly-
merase and Nco1 and SP6 RNA polymerase combinations, respec-
tively. Probes were made with an mMESSAGE mMACHINE kit
(Ambion) and purified with mini Quick Spin Columns (Roche).
RNA Extraction from Mouse Skeletal Tissue and
Whole Transcriptome Sequencing
Total RNA frommicrodissected whole limb buds from time-mated
C57BL/6 embryonic day (E) 12.5 mice was prepared with the Illu-
mina TruSeq Total RNA LT kit to deplete rRNA. For tibial tissue
RNA preparation from E15, E17, and adult Swiss Webster mice,
hindlimbs were removed and tibiae were dissected from associated
muscular tissue. For periosteal cell isolation from juvenile mice,
periosteum was excised by a lengthwise scalpel cut along the
dissected tibia and careful removal of the periosteum with
watchman forceps. Tissue from this procedure, as well as frommi-
crodissected whole limb buds from time-mated C57BL/6 E10.5
mice, was collected in Trizol, homogenized, and RNA extracted
as per the manufacturer’s recommendations. RNA was subse-
quently concentrated with a NucleoSpin RNA column (Macherey
Nagel). For transcriptome sequencing, RNA was normalized and
sequenced on an Illumina HiSeq 2500 and the paired-end protocol
was used. Sequence reads were filtered for quality and mapped
to the mouse reference sequence (mm9) with TopHat19 and the
iGenomes annotation. Duplicate reads were marked with Picard.
Alignments were visualized and plottedwith the Integrative Geno-
mics Viewer.
In Vitro Mineralization Assay
Early passage MC3T3E1 (American Tissue Culture Collection;
clone 4) cells were seeded in 6- or 24-well culture plates at
53 104105 cells/cm2. After 24 hr, we transfected cells with phos-
phorothioate oligonucleotides (TriLink Biotechnologies) by using
RNAiMAX (Life Technologies) according to the manufacturer’s
protocol. Matrix mineralization was initiated 24 hr after transfec-
tion by the addition of ascorbic acid and beta-glycerophosphate
(final concentrations of 50 mg/ml and 10 mM, respectively). Com-
plete media changes were performed every three days. Mineraliza-
tion was assessed at 12 days with Alizarin red (Sigma-Aldrich). The
Met- skipping oligo sequence was 50-20O-Me-AGU GUGUACUCU
UGC GUC AU-30. The control-scrambled oligo sequence was
50-20O-Me-AUG ACG CAA GAG UAC ACA CU-30.
RNA Extraction and qRT-PCR for Markers of
Ossification
We extracted RNA from transiently transfectedMC3T3E1 (clone 4)
cells on day four after transfection by using a NucleoSpin RNA kit
(Mackerey Nagel). RNA was treated with a TURBO DNA-free Kit
(AM1907, Life Technologies) and cDNA was prepared with Super-
Script III reverse transcriptase (LifeTechnologies). qRT-PCRwasper-
formed according to the manufacturer’s specifications with the
LightCycler 480 SYBR Green I Master kit (Roche) and run on a
LightCycler 480 instrument. Results were analyzed with Qbase.20Results
OFD Lesions Exhibit Active Marginal Osteogenesis
We sought to extend our understanding concerning the
zonal architecture of the lesions inOFD, including staining
formarkers of osteoblasts and osteoclasts in addition to cell840 The American Journal of Human Genetics 97, 837–847, Decembproliferation. Analysis of lesional tissue from affected indi-
vidual III:6 from family 1 displayed the typical zonal archi-
tecture of OFD (Figure 1B), as previously reported for
family 27. Staining for proliferating cell nuclear antigen
(PCNA) demonstrated that the centrally located spindle-
shaped cells were not mitotically active but that the cells
rimming these lesions stained for markers of osteoblastic
differentiation (osterix, OSX; alkaline phosphatase, ALP).
Osteoclasts staining for tartrate resistant acid phosphatase
(TRAP) were also prominent at the periphery of the lesions
(Figure S1). On the basis of these and previous observa-
tions5 demonstrating that the centrally located cells
stained positively for markers that are associated with un-
differentiated mesenchymal cells, we hypothesized that
the pathogenesis of familial OFD was related to a delay
in osteogenesis, with lesions resolving at the margins
through the action of rimming osteoblasts and osteoclasts.
Mutations in MET Cause Familial OFD
The majority of previous clinical and histological studies
on OFD concentrated on the unilateral, presumptive spo-
radic forms of the condition. To extend understanding of
the etiology and pathogenesis of OFD, we initiated a study
of four families with bilateral disease, three of them
affected by OFD that segregated as an autosomal-dominant
trait (Figure 1C). The ascertainment of rare familial in-
stances of OFD presented the opportunity to locate a
genetic regulator of osteogenesis that, considering the
location of the lesions, was likely to relate to the periosteal
contribution to this process. To identify the causative locus
for familial OFD, we genotyped family 1 (Figure 1C) for
linkage analysis by using HumanLinkage-12 arrays (Illu-
mina) under a model of autosomal-dominant inheritance
with incomplete penetrance. The two most significant re-
gions, but with submaximal LOD scores, were identified
on chromosomes 7 and 11 (Figure S2). Targeted capture
of all coding and phylogenetically conserved elements
(4.76 Mb of a combined 44 Mb region) within these
two candidate regions was followed by massively parallel
sequencing from three affected individuals (III:8, IV:2,
and IV:8) with the Roche 454 system. Only one
non-synonymous variant not represented in dbSNP build
131 or the Exome Variant Server was shared by all
three individuals —a 26 bp deletion (c.3010_3028þ8del
~~[p.Leu964_Asp1010del]) that included the donor splice
site at the exon 14 and intron 14 junction of MET
(GenBank: NM_000245.2; Figure 1C; Table 1; Tables S1
and S2), the gene that encodes the receptor tyrosine kinase
MET. Family 2 was analyzed by a similar mapping and
sequencing strategy. In this family, exome sequencing
of four individuals revealed a second MET variant
(c.3028þ1G>T) at the phylogenetically invariant þ1 posi-
tion of the 30 splice donor site of the same exon (Table 1;
Figure 1C; Table S3). The same mutation was found in an
affected mother and one son in family 3. To test whether
the two identical mutations in families 2 and 3 had arisen
as independent events, we constructed haplotypes byer 3, 2015
Table 1. Mutations in MET and Penetrance in Bilateral Osteofibrous Dysplasia
Mutation Penetrancea
Bones AffectedDNA Protein Penetrant Non-penetrant
Family 1, familial c.3010_3028þ8del p.Leu964_Asp1010del 10 1 T, F, U
Family 2, familial c.3028þ1G>T p.Leu964_Asp1010del 6 4 T, F
Family 3, familial c.3028þ1G>T p.Leu964_Asp1010del 2 0 T, F
Family 4, simplex c.3028þ1G>T p.Leu964_Asp1010del 1 0 T, F; bilateral
Reference transcript, GenBank: NM_000245.2. Abbreviations are as follows: F, fibula; T, tibia; U, ulna.
aNumbers indicate the number of mutation-carrying family members who are affected (penetrant) versus unaffected (non-penetrant).using flanking polymorphic microsatellite markers (Table
S5). Results indicated that the c.3028þ1G>T mutations
had arisen on different haplotypes in families 2 and 3
(Figure S3). The c.3028þ1G>T mutation was also observed
in DNA extracted from normal tissue adjacent to an
excised lesion from the affected individual in family 4.
The presentation in this instance was that of bilateral
OFD as previously reported,9 but insufficient DNA pre-
vented complete verification of the haplotype on which
this variant arose. Parental DNA samples were also unavai-
lable, and therefore wewere unable to confirmwhether the
mutation arose de novo in the germline, was an early post-
zygotic mutation, or had been inherited from a parent.
These MET variants segregated throughout families 1–3
in all affected and in four non-penetrant individuals (Ta-
ble 1; Figure S4).
The variants identified in all four families affect the ca-
nonical splice-donor consensus sequence for exon 14 of
MET. To assess the consequences of these mutations, we
performed RT-PCR on cDNA prepared from cultured
dermal fibroblasts (family 1), lymphoblastoid cell lines
(family 2), and excised lesional tissue from bone (family
3) by using primers located in exons flanking exon 14
(Figure 2A). Both the 26 bp deletion and the
c.3028þ1G>T variants in MET were shown to result in
the exclusion of exon 14 of MET from the mature tran-
script (METD14; Figure 2A). In all instances, compared to
the WT allele, this splice form was not associated with
instability, as judged by the presence of both transcripts
in the respective sequence chromatograms.
Consistent with mutations in MET being causative of
OFD, immunohistochemical staining in lesion tissue re-
vealed the presence of MET in both osteoblasts and osteo-
clasts (Figure 2B). Additionally, western blot analysis of
lesional tissue obtained from an affected individual from
family 3 revealed detectable levels of MET, as did an assay
on metaphyseal bone obtained from an age-matched
healthy individual (Figure 2B). At the protein level, exclu-
sion of exon 14 from the spliced transcript predicts the in-
frame omission of a 47-amino-acid juxtamembrane
domain (JMD) from the MET receptor (Figure 2C),
although the resolution of western blot analysis is insuffi-
cient to differentiate this METDJMD isoform from a receptor
protein that retains the JMD.The AmericanBoth the 26 bp deletion and the c.3028þ1G>T variant
have the same consequence—the in-frame deletion of
exon 14 that encodes the phylogenetically conserved
JMD of the MET receptor. The JMD regulates MET receptor
stability and subcellular localization. Engagement of MET
with its sole known ligand, hepatocyte growth factor
(HGF), leads to homodimerization of the receptor and
phosphorylation of at least five tyrosine residues located
in its cytoplasmic domain.21 Whereas four of these phos-
photyrosine residues are known to initiate the assembly
of protein complexes that mediate signal transduction,
phosphorylation of Tyr1003 within the JMD leads to its
engagement with the ubiquitin ligase, CBL.22 Receptor
ubiquitination within the JMD regulates MET endocytosis,
downregulation of plasmamembrane receptor abundance,
and endosomal degradation and/or recycling of internal-
ized receptors.23,24 Consistent with Tyr1003 being located
within the exon-14-encoded JMD, previous work has
demonstrated that exclusion of this protein domain from
MET attenuates receptor internalization and recycling
and upregulates the duration of ligand-dependent
signaling.10,25 Furthermore, somatically acquired muta-
tions in lung10,26–28 and gastric cancer29 that lead to splice
exclusion of exon 14, and hence aberrant levels of METD14,
have been shown to prolong ligand-induced mitogen-acti-
vated protein kinase (MAPK) signaling as a result of stabili-
zation of MET and enhanced retention of MET receptors at
the plasma membrane.10,29 The observation that similar, if
not identical, germline mutations lead to OFD directly im-
plicates MET as a developmental regulator of osteogenesis
through a similar gain-of-function mechanism.
MET Exon 14 Skipping Occurs during Development
in Mice
Splice exclusion ofMET exon 14 (or orthologous sequences
in other species) might be a developmentally regulated
event. Splice forms orthologous to METD14 have been de-
tected in embryonic and postnatal rats and mice,25,30,31
although data are lacking on the spatial and temporal regu-
lation of these splice forms. Given the strong immuno-
staining for MET in osteoclasts and osteoblasts rimming
OFD lesional tissue (Figure 2B), we sought evidence for
expression of Met transcripts lacking the orthologous
exon to human exon 14 (mouse exon 15; MetD15) inJournal of Human Genetics 97, 837–847, December 3, 2015 841
Figure 2. Expression of MET in Familial OFD
(A)MET splicing and expression in germline and OFD lesional tissue. (i) RT-PCR of cDNA from lymphoblastoid cell lines obtained from a
normal control (lane 2), a lung cancer cell line (H596)10 with a mutation conferring constitutive skipping of exon 14 (lane 3), and lym-
phoblastoid cell lines from two affected individuals (IV:10, IV:12; Figure 1C) from family 2 (lanes 4 and 5). Primers designed to exons 13
and 15 amplified a 507 bp product in exon-14-inclusive templates and a 367 bp fragment in mutant-exon-14-excluded transcripts. (ii)
Sequence verification from gel-excised RT-PCR products confirming exon 14 exclusion in transcripts from two affected individuals from
families 1 and 2. (iii) RT-PCR with primers complementary to exons 13 and 15 and cDNA prepared from cells liberated from an OFD
lesion. Control cells were grown from a femoral metaphyseal biopsy from an unrelated age-matched subject. FL, full-length METþ14
product; D, METD14 product.
(B) MET protein is detectable in OFD lesions and normal bone. (i) Western blot of cell lysates from lesional OFD tissue demonstrating
MET in lesional tissue (OFD) and in metaphyseal bone from a healthy age-matched control subject. (ii) Immunohistochemistry of le-
sional tissue from subject III:6 (family 1) demonstrating MET immunoreactivity in rimming osteoblasts (red arrows) and osteoclasts
(black arrows). o, osteoid.
(C) Schematic diagram of MET showing position of mutations and consequences to receptor structure conferred by the mutations
affecting the splice donor site leading to exclusion of the cytoplasmic JMD (yellow).normal developing mouse skeletons. Preparations from
either whole dissected mouse embryonic limb buds
collected at E10.5 or tibiae collected at E15, E17, and adult
time points showed consistent but low-level expression of
MetD15 (Figure 3A). In situ hybridization of a riboprobe de-
signed to detect both MetD15 and Metþ15 in mouse E15
tibiae revealed prominent expression of Met in chon-
drocytes and, of relevance to the site of lesion formation
in OFD, in the periosteum of long bones (Figure 3B).
Furthermore, RNA sequencing (RNA-seq) analysis of RNA
extracted from E12.5 mouse limb buds revealed the expres-
sion of both full-length and skipped isoforms in forelimbs
and hindlimbs (Figure 3C; Figure S5).
Because Met exon 15 skipping occurred physiologically
and Met expression was prominent in embryonic perios-
teum, we sought evidence that Met exon 15 skipping
occurred specifically in this tissue. Because the in situ hy-
bridization study (Figure 3B) did not discriminate between
the full-length exon-inclusive (Met15þ) and exon-exclusive
(MetD15) isoforms, we isolated a proliferating cell popula-
tion from in vitro culture of explanted dissected perios-
teum from a 3-week-old mouse and showed evidence for842 The American Journal of Human Genetics 97, 837–847, Decembproduction of both MetD15 and Met15þ transcripts by RT-
PCR (Figure 3D). These results suggested that exon 15
splice exclusion was active in the periosteum during
normal development. The germline mutations that we
have shown to underlie OFD and subvert exon 14 skipping
therefore have the potential to influence periosteal func-
tion and lead to the osseous lesions observed in OFD
through the aberrant production of a MET receptor lacking
the JMD domain (METDJMD).
Diminished Osteoblastic and Osteoclastic Function
Resulting from MET Exon Skipping
MET levels are prominent in both osteoblasts and osteo-
clasts in OFD lesional tissue (Figure 2B; Figure S1) and in
normal bone.32 To address the possibility that OFD is pri-
marily due to a defect in osteoblast function, we assessed
the effect of the MetD15 splice form in an in vitro assay of
osteoblastic differentiation. We designed and validated
20-O-methyl-oligoribonucleotides that can induce exon
15 splice exclusion when transfected into mouse cell lines
(Figures 3A and 4A). Using the mouse MC-3T3 pre-osteo-
blastic cell line,33 we measured the effect of induceder 3, 2015
Figure 3. Met Expression and Exon 15 Splice Exclusion during Mouse Skeletal Development
(A) RT-PCR of exons 14–16 ofMet using cDNA prepared from developing mouse limbs at E10 (whole limb), E15, and E17 and from adult
(A) mouse limbs (all from dissected tibia). C2C12 cells alone (–ON) and cells transiently transfected with 2-O-methyl oligoribonucleotide
(þON) to induce exon 15 exclusion are shown. FL, full-length exon 15-inclusive product; D, exon 15-excluded product; W, no cDNA
control; RT, no reverse transcriptase control.
(B) In situ riboprobe staining of mouse E15.5 tibial diaphysis for Met. Strong expression of Met is demonstrated in the periosteum. The
scale bar represents 200 mm.
(C) RNA-seq split reads spanningmultiple exons for bothMetD15 andMet15 isoforms obtained from RNA isolated from E12.5 mouse fore-
limb and hindlimb buds.
(D) RT-PCR with RNA from cells cultured from periosteum dissected from the tibial diaphysis of a 3-week-old mouse. D, MetD15; FL,
Met15þ; RT, minus reverse transcriptase control; P, periosteal cDNA.MetD15 exon skipping at 4 days by using RT-PCR for multi-
ple markers of osteogenic differentiation and at 12 days by
using alizarin red to assess matrix mineralization. At day 4
after the induction of exon exclusion, the osteoblastic
marker Alp showed significantly reduced expression (p <
0.05), whereas Rankl, an osteoblast-derived osteoclasto-
genic factor, showed elevated expression (p < 0.01,
Figure 4B). Early markers of osteoblastic differentiation
(Osx, Runx2) and Col1a1 were not significantly altered by
induction of MetD15 expression, indicating that either the
level of exon skipping achieved by the oligoribonucleotide
was insufficient to have an effect on these functions or that
MetD15 does not impact the earliest phases of osteoblastic
differentiation. At day 12, matrixmineralization wasmark-
edly repressed in these cells compared to mineralization in
cells transfected with a scrambled control oligoribonucleo-
tide (Figure 4C). These results support the hypothesis that
a forced overexpression of MetD15 relative to Metþ15
conferred a block in progression to late stages of osteoblast
differentiation. Furthermore, these data suggest that phys-
iological deployment of this event might regulate the
speed at which osteoblasts transition to more differenti-
ated states during skeletogenesis.
Somatic Mutation of Tyr1003 in Unilateral OFD
To testwhether themutational basis of familialOFDwas the
same in sporadic, unilateral cases of the disorder, DNA ex-
tracted from 20 formalin-fixed, paraffin-embedded tissue
samples from individuals with sporadically occurring, uni-
lateral OFD were Sanger-sequenced across exon 14 of MET,
including the flanking intron-exon boundaries. No muta-
tions predicted to lead to disturbance of exon 14 splicing
were found in these samples, although low levels of mosai-
cismcouldnot be excludedby this technique. An additionalThe Americanlesional samplewas expanded in culture and then subjected
to exome sequencing, revealing a missense mutation in
exon 14, c.3008A>C (p.Tyr1003Ser). This substitution af-
fects the phosphorylation site (Tyr1003) known to regulate
JMD-mediated receptor ubiquitination and recycling34
through binding of the ubiquitin ligase CBL.22 Eight clonal
cell lines six of which were shown not to have the
c.3008A>C variant, were isolated from this lesion, indi-
cating that it was somatically acquired (Figure 5A). RT-PCR
followed by Sanger sequencing of lesional tissue demon-
strated thepresenceofbothWTandmutantalleles, confirm-
ing that the mutation had not arisen as an artifact in vitro.
METDJMD and METp.Tyr1003Ser Receptors Are Resistant
to CBL-Mediated Destabilization
Previous work in cancer cell lines and transient transfec-
tion experiments have indicated that the JMD and phos-
phorylation of Tyr1003 regulate the ubiquitination of
MET at the plasma membrane, hence its stability and
signaling half-life.10,25,28 Therefore, we sought to investi-
gate whether the familial METD14 mutations and the so-
matic p.Tyr1003Ser substitution affected CBL-mediated
receptor degradation as previously indicated.10 Using a
transient transfection approach in HEK293 cells, we intro-
duced human constructs of MET incorporating either a
deletion of exon 14 or the p.Tyr1003Ser variant into cells
alongside either the ubiquitin ligase CBL or an unrelated
ubiquitin ligase, SIAH1. CBL-dependent MET receptor sta-
bility was assessed by western blot analysis. The results
showed that in the presence of CBL, but not of the unre-
lated ubiquitin ligase SIAH1, WT MET was destabilized,
whereas the METD14 and METp.Tyr1003Ser mutations ablated
the sensitivity of MET to the effects of CBL (Figure 5B).
These results indicate that the germline and somaticJournal of Human Genetics 97, 837–847, December 3, 2015 843
Figure 4. Skipping of Met Exon 15 in
Mice Impairs Both Osteoclast and Osteo-
blast Function
(A) Induced MC-3T3 cells with and
without treatment with exon-skipping or
scrambled control 2-O-methyl oligoribo-
nucleotides assayed for the presence or
absence of skipped and unskipped Met
transcripts by RT-PCR.
(B) qRT-PCR for osteoblastic markers
4 days after induced osteoblastic differenti-
ation of MC-3T3 cells with AAP (ascorbic
acid, glycerol phosphate) and transfection
with exon-skipping or scrambled control
oligoribonucleotides. Transcripts assayed
were Runx2b, Osx, Col1a1, Alp, and Rankl.
n ¼ 7; CNRQ, calibrated normalized rela-
tive quantities; scale bars represent SEM,
*p < 0.05; **p < 0.01, paired two-tailed
Student’s t test.
(C) Endpoint matrix mineralization assay
(alizarin red) 12 days after AAP induction.
Oligoribonucleotides were re-applied to
cultures every 3 days.mutations that underlie OFD stabilize the MET receptor
and, as such, confer a gain of function to the protein.Discussion
These genetic, cellular, and biochemical data indicate that
OFD is caused by MET mutations that can be inherited or,
occasionally, somatically acquired. In our series, all bilat-
eral cases were caused bymutations that result in exclusion
of exon 14 (METD14), whereas a single instance of sporadi-
cally arising unilateral OFD was associated with a somatic
missense mutation within the JMD encoded by exon 14.
Both mutational mechanisms exert the same effect—they
stabilize MET, an effect that relates to the role that the
JMD plays in mediating receptor recycling and degrada-
tion.10 Phosphorylation of residues within the JMD,
including Tyr1003, results in receptor internalization to
the endosomal compartment, where they can either
continue to signal,35 be redirected back to the cell mem-
brane, or undergo degradation.34
Limited evidence exists to implicate a developmental
role for MET in skeletogenesis. Mouse models of Met
overexpression or insufficiency are characterized by
placental, muscle, and liver developmental anomalies
and do not exhibit detectable skeletal developmental phe-
notypes.36–39 These data are not necessarily inconsistent
with our experiments linking mutations in MET with a
skeletal disorder because these gain-of-function mutations
act through a ligand-dependent mechanism, and therefore
its effect is spatially restricted to tissues in which bothMET
and HGF are normally co-localized.844 The American Journal of Human Genetics 97, 837–847, December 3, 2015Mutations similar to those reported
here that lead to splice exclusion of
exon 14 have been reported as so-matic events in gastric cancer,29,40 lung cancer,26,27,41,42
and other tumors.28 In lung cancer, these variants have
been suggested to be probable driver mutations, acting in
concert with other oncogenic mutations, to protract
ligand-dependent signaling mediated by MET through
prolongation of receptor occupancy at the plasma mem-
brane.10,28 Anecdotal evidence suggests that treatment of
individuals with lung tumors and METD14 mutations
with MET-antagonist drugs leads to a favorable clinical
response, implying that the clinical resolution of OFD in
individuals who have a mutation at this locus might also
be hastened by treatment with these same agents.
The MET-HGF axis is well described as a mediator of the
early developmental program known as the epithelial-
mesenchymal transition.43,44 In this scenario, HGF pro-
duction is restricted to mesenchymal cells, where it is
secreted in an paracrine fashion to activate MET receptors
in epithelial cells, stimulatingmesenchymal transition and
cell dispersal. Uncoupling of this mechanism can lead to
oncogenic activation in certain cell types.34 The mecha-
nism by which exclusion of the functional JMD in MET
leads to OFD differs from the activating germline missense
mutations affecting the tyrosine kinase domain of MET,
which are associated with a predisposition to develop renal
papillary carcinoma. In the latter instance, ligand-inde-
pendent signal activation leads to tumor formation,45
whereas in OFD, the gain of function is dependent on
engagement of the receptor with its ligand, HGF.10 Conse-
quently, the requirement for HGF could be one factor that
explains the different clinical presentations of these two
allelic disorders. The gain of function in OFD might there-
fore only manifest in tissues that possess significant levels
Figure 5. Mutations in MET Render the Receptor Insensitive to CBL-Mediated Degradation
(A) Of eight clonal lines isolated from primary lesional tissue, Sanger sequencing confirmed the presence of the c.3008A>C mutation
(mutant) predicting the p.Tyr1003Ser substitution in two, and six clonal cell lines were WT (wild-type). Genomic DNA was extracted
from a fragment of uncultured lesional tissue (tissue), and sequencing showed the presence of both alleles, demonstrating that the mu-
tation was somatically acquired in this individual.
(B) OFDmutations stabilize MET in the presence of the ubiquitin ligase CBL. HEK293F cells were transfected with equal amounts of WT
MET-GFP (lanes 1–3), METp.Tyr1003Ser-GFP (lanes 4–6), and METD14-GFP (lanes 7–9). Cells were co-transfected with equal amounts of a
construct encoding SIAH1, an unrelated ubiquitin ligase (lanes 2, 5, and 8) or c-CBL-DDK (lanes 3, 6, and 9). The level of WT MET-
GFP b-chain is reduced (relative to MET precursor) in the presence of CBL but not of SIAH1. The destabilizing effect of CBL is not evident
in the presence of MET constructs with the p.Tyr1003Ser or D14 variants. This blot is an illustrative example of three independent
experiments.of ligand, although it remains enigmatic as to why lesions
manifest predominantly within the tibia and fibula and
not in other skeletal components. In this respect, OFD is
reminiscent of the tibial lesions observed in a minority of
individuals with neurofibromatosis type 1. In this condi-
tion, functional haploinsufficiency for NF1, the product
of which represses RAS-MAPK signaling, also predisposes
individuals to pseudoarthrosis of the tibia. However, there
are key differences between the two diagnoses. For
example, the tibial lesions typically do not self-resolve in
NF1, and evidence exists that a second mutational event
is required to give rise to an NF1 tibial lesion.14,46–48 The
question still remains as to why it is the tibial diaphysis
that has a diathesis to develop lesions when MAPK
signaling is increased. Possibilities include vascular or me-
chanical factors or the presence of a hypoxic or vascular
watershed that could influence MET expression and ac-
tivity.49,50
Data reported here show that exclusion of the JMD in
MET alters osteoblastic function in vitro and that this
same mechanism could be the predominant factor that
produces OFD lesions. Osteoblasts and osteoclasts are
known to co-regulate one another, however, and MET
and HGF also participate in reciprocal signaling between
these two cell types, leaving open the possibility that oste-
oclastic functions are also impaired in this condition.32
Given the potential for such complexity, modeling this
condition in the mouse might improve our understanding
of the cellular basis for the pathogenesis of OFD and the
wider role that MET plays in osteogenesis.
The regulation of periosteal osteoprogenitor cell differ-
entiation and function is presently poorly understood
despite this cell pool being a major contributor to fracture
repair51,52 and cortical bone mass.25,26 Our results suggest
that MET-mediated signaling is a regulator of osteogenesis
in the tibial and fibular diaphysis, and this insight offersThe Americannew avenues to explore the possibility of therapeutically
altering these processes under circumstances when bone
repair and maintenance needs to be enhanced or
sustained.Supplemental Data
Supplemental Data include five figures and five tables and can be
found with this article online at http://dx.doi.org/10.1016/j.ajhg.
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